Eosinophilic Granulomatosis with Polyangiitis

Comprehensive Guide: Eosinophilic Granulomatosis with Polyangiitis (EGPA)

1. Introduction & Overview

Eosinophilic Granulomatosis with Polyangiitis (EGPA), historically known as Churg-Strauss Syndrome, is a rare, systemic, small-to-medium vessel necrotizing vasculitis. It is characterized by the triad of asthma, peripheral blood eosinophilia, and extravascular eosinophilic inflammation.

As a member of the ANCA-associated vasculitis (AAV) family, EGPA represents a complex immunological dysregulation. Unlike other AAVs (such as Granulomatosis with Polyangiitis or Microscopic Polyangiitis), EGPA is uniquely driven by eosinophil-mediated tissue damage, affecting multiple organ systems including the respiratory tract, skin, peripheral nerves, heart, and gastrointestinal tract. Clinical management requires a multi-disciplinary approach involving rheumatology, pulmonology, and immunology to mitigate the significant morbidity associated with late-stage organ involvement.

2. Pathophysiology and Etiology

The etiology of EGPA remains idiopathic, though it is understood as a complex interplay between genetic predisposition and environmental triggers.

Mechanisms of Disease

The pathophysiology of EGPA is rooted in a T-helper 2 (Th2) cell-mediated immune response. This leads to the overproduction of cytokines, specifically Interleukin-5 (IL-5), IL-4, and IL-13.
* Eosinophilic Infiltration: IL-5 is the primary cytokine responsible for the maturation, activation, and survival of eosinophils. These cells infiltrate tissues, releasing cytotoxic granules (e.g., major basic protein, eosinophil peroxidase), leading to tissue necrosis.
* ANCA Production: Approximately 30-40% of patients are positive for Antineutrophil Cytoplasmic Antibodies (ANCA), typically directed against myeloperoxidase (MPO-ANCA). The presence of ANCA often correlates with a more "vasculitic" phenotype (e.g., glomerulonephritis, mononeuritis multiplex).
* Vessel Damage: The combination of eosinophil-induced inflammation and ANCA-mediated endothelial cell activation results in necrotizing vasculitis.

3. Clinical Staging and Presentation

EGPA traditionally follows a three-phase clinical progression, though these phases may overlap or occur simultaneously in clinical practice.

Standard Clinical Indications

• Respiratory: Asthma is the hallmark, often refractory to standard therapy and worsening prior to the onset of vasculitis.
• Neurological: Mononeuritis multiplex (asymmetric peripheral neuropathy) is the most common neurological manifestation, occurring in up to 75% of patients.
• Dermatological: Palpable purpura, subcutaneous nodules, and urticaria.
• Cardiac: The leading cause of mortality in EGPA. Manifests as eosinophilic myocarditis, heart failure, or pericarditis.

4. Differential Diagnosis

Differentiating EGPA from other eosinophilic and vasculitic disorders is critical for treatment selection.

• Hypereosinophilic Syndrome (HES): Lacks the allergic/asthmatic history characteristic of EGPA.
• Granulomatosis with Polyangiitis (GPA): Usually presents with upper respiratory tract destruction and granulomatous inflammation, typically without severe asthma or high eosinophil counts.
• Asthma with Eosinophilia: Often confused with EGPA; however, this lacks the systemic vasculitic components (e.g., neuropathy, glomerulonephritis).
• Drug-induced Eosinophilia: Must rule out reactions to medications (e.g., sulfonamides, antibiotics) that can mimic eosinophilic syndromes.

5. Diagnostic Testing

Diagnosis relies on the 1990 American College of Rheumatology (ACR) criteria and the 2022 ACR/EULAR classification criteria.

Key Diagnostic Markers

1. Complete Blood Count (CBC): Peripheral blood eosinophilia (typically >10% or >1,500 cells/µL).
2. Serology: ANCA testing (MPO-ANCA). Note: A negative ANCA result does not rule out EGPA.
3. Imaging: Chest X-ray or HRCT to assess for pulmonary infiltrates or opacities.
4. Tissue Biopsy: The gold standard. Biopsies of affected organs (skin, lung, or nerve) reveal eosinophilic infiltration and necrotizing vasculitis.
5. Pulmonary Function Tests (PFTs): To evaluate obstructive patterns related to asthma.
6. Cardiac Evaluation: Echocardiogram or Cardiac MRI to detect eosinophilic myocarditis.

6. Treatment Protocols and Prognosis

Standard Therapy

• Remission Induction: High-dose systemic corticosteroids (prednisone) are the cornerstone. In severe cases (organ-threatening disease), cyclophosphamide or rituximab is utilized.
• Maintenance: Tapering steroids while using steroid-sparing agents like azathioprine or methotrexate.
• Biologics: Mepolizumab (anti-IL-5) has been FDA-approved for the treatment of EGPA, showing significant success in reducing relapse rates and steroid dependency.

Prognosis

The prognosis is determined by the Five-Factor Score (FFS), which evaluates:
* Age > 65
* Cardiac insufficiency
* Renal insufficiency (Creatinine > 1.58 mg/dL)
* Gastrointestinal involvement
* Central nervous system involvement

Patients with a high FFS require more aggressive immunosuppressive induction therapy. Long-term prognosis is generally good with early intervention, though chronic asthma management and monitoring for vascular relapse remain lifelong requirements.

7. Risks, Side Effects, and Contraindications

Treatment for EGPA involves potent immunosuppressants.
* Corticosteroids: Risk of osteoporosis, diabetes, hypertension, and opportunistic infections.
* Cyclophosphamide: Risk of hemorrhagic cystitis, bladder cancer, and infertility. Requires prophylactic hydration and monitoring of the urinary tract.
* Rituximab/Mepolizumab: Potential for infusion-related reactions and serious infections (e.g., shingles, pneumonia).

8. Frequently Asked Questions (FAQ)

1. Is EGPA the same as asthma?
No. While asthma is a major component, EGPA is a systemic autoimmune disease where eosinophils attack blood vessels. Asthma is usually the first sign, but the disease progresses far beyond the lungs.

2. Can EGPA be cured?
There is no "cure," but it is highly treatable. Many patients achieve long-term clinical remission with medications, allowing them to lead normal lives.

3. Why is cardiac involvement so dangerous in EGPA?
Eosinophils are toxic to the heart muscle. Eosinophilic myocarditis can lead to rapid heart failure or arrhythmias, making it the primary cause of death in these patients.

4. What is the role of ANCA in EGPA?
ANCA are antibodies that signal a more "vasculitic" presentation. However, roughly 60% of EGPA patients are ANCA-negative, meaning they may have more eosinophilic-dominant symptoms (like asthma/sinusitis) rather than classic vessel damage.

5. How is Mepolizumab different from steroids?
Mepolizumab specifically targets IL-5, the protein that makes eosinophils grow. It is a "steroid-sparing" agent, meaning it helps patients lower their reliance on high-dose prednisone.

6. Does the disease come back (relapse)?
Yes, relapse is common. Patients require lifelong monitoring by a rheumatologist to detect early signs of a flare.

7. Is EGPA hereditary?
No, there is no evidence that EGPA is directly passed down through families, though there may be a subtle genetic predisposition to autoimmune disorders.

8. Can I live a normal life with EGPA?
With modern treatments, the vast majority of patients achieve remission and maintain a good quality of life, provided they adhere to their medication schedule.

9. What should I look for during a flare?
Watch for worsening asthma, new skin rashes, numbness/tingling in hands or feet, abdominal pain, or unexplained fevers.

10. What kind of doctor treats EGPA?
A rheumatologist is the primary specialist. However, you will likely also be managed by a pulmonologist (for asthma) and potentially a cardiologist or neurologist depending on the organs affected.

9. Conclusion

Eosinophilic Granulomatosis with Polyangiitis is a complex, multi-system disorder that exemplifies the necessity of precision medicine. By integrating advanced immunological therapies with traditional immunosuppression, clinicians can significantly alter the disease trajectory. Early recognition of the prodromal asthmatic phase and prompt referral to specialized centers remain the most critical factors in improving patient outcomes. Continuous monitoring, patient education, and a proactive approach to potential organ damage are the hallmarks of successful clinical management in this challenging vasculitic condition.